The global dyslipidemia therapeutics market, valued at US$ 41.55 billion in 2023, is projected to expand at a compound annual growth rate (CAGR) of 2.5% over the next decade. According to a market study by Fact.MR, global demand for dyslipidemia therapeutics is expected to reach a market revenue of US$ 53.2 billion by the end of 2033.
Dyslipidemia, characterized by abnormal lipid levels...
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek